| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Angus K Jacobs, Steven D Morley, Kay Samuel, Katie Morgan, Lyndsey Boswell, Timothy J Kendall, David A Dorward, Jonathan A Fallowfield, Peter C Hayes and John N Plevris |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| University of Edinburgh Hepatology Laboratory internal funding |
|
| the Liver Endowment Funds of the Edinburgh & Lothian Health Foundation |
|
|
| Corresponding Author |
Angus K Jacobs, BSc, Research Assistant, Hepatology Laboratory, University of Edinburgh, Chancellor’s Building, Edinburgh BioQuarter, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom. angus.jacobs@ed.ac.uk |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Angiotensin-converting enzyme 2; Immunohistochemistry; COVID-19; COVID-19-associated cholangiopathy |
| Core Tip |
There has been much recent interest in angiotensin-converting expression enzyme 2 (ACE2) as the fulcrum of the ‘anti-inflammatory’ renin-angiotensin system pathway because severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease-19 (COVID-19), targets ACE2 for viral attachment and host cell invasion. Previously ACE2 mRNA has been measured in metabolic dysfunction-associated steatotic liver disease (MASLD) and COVID-19 infection but, uniquely, we used immunohistochemistry, alongside measurement of fibrosis and lipid, to show that ACE2 protein levels and hepatic lipid content are correlated across the MASLD pathophysiological spectrum and in COVID-19 patients showing evidence of liver injury. Hepatic lipids are also associated with the presence of SARS-CoV-2 virus in the liver suggesting a possible functional link. |
| Publish Date |
2024-08-13 08:00 |
| Citation |
<p>Jacobs AK, Morley SD, Samuel K, Morgan K, Boswell L, Kendall TJ, Dorward DA, Fallowfield JA, Hayes PC, Plevris JN. Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19. <i>World J Gastroenterol</i> 2024; 30(31): 3705-3716</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i31/3705.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i31.3705 |
